Assessment of quality of life in patients with uncontrolled <i>vs.</i> controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL)

Trepp, Roman; Everts, Regula; Stettler, Christoph; Fischli, Stefan; Allemann, Sabin; Webb, Susan M.; Christ, Emanuel

doi:10.1111/j.1365-2265.2005.02307.x

Cited by 82 publications

(76 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is the first study to report on the use of AcroQoL in a nationwide registry with controlled and uncontrolled patients. Median AcroQoL total and subscores are comparable with those reported earlier for acromegalic patients in remission (5,7,14,20,21), and higher than that in active acromegaly (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20).…”

Section: Discussionsupporting

confidence: 71%

See 1 more Smart Citation

Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian Registry on acromegaly

et al. 2007

View full text Add to dashboard Cite

Objective: To assess the impairment of quality of life (QoL), evaluated by the acromegaly QoL (AcroQoL) questionnaire, in patients with controlled and uncontrolled acromegaly. Design: Cross-sectional evaluation of AcroBel, a national observational registry of acromegalic patients newly diagnosed or in follow-up. Methods: Disease perception by the patients was evaluated by the disease-specific signs and symptoms score (SSS) and QoL was assessed by the AcroQoL questionnaire. Hormonal status was determined by central measurements of GH and IGF-I. Results: Patients (nZ291) had a median GH of 1.43 mg/l (0.65-3.03; IQR), a median IGF-I of 231 mg/l (150-367), and a mean IGF-I z-score of C1.91 (S.D. 2.21). The AcroQoL total score in the whole group was 67.1 (51.1-78.4), with a score of 65.6 (43.8-78

show abstract

Section: Discussionsupporting

confidence: 71%

“…In contrast, in the study by Trepp et al, patients with uncontrolled acromegaly had significant lower HRQoL than patients in remission or with a discordant remission status (20). However, this was a single-centre study with rather small numbers of patients.…”

Section: Discussioncontrasting

confidence: 43%

Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian Registry on acromegaly

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In contrast to some studies we did not find an effect of IGF1 SDS or disease control on QoL (10,11,12,13). One possibility is that only 13 of our total cohort of 108 patients were not biochemically controlled resulting in a group that is too small to detect differences.…”

Section: Discussioncontrasting

confidence: 54%

“…Furthermore, they found no effect of remission status on QoL. Thus, controversy exists because these findings are in contrast to previous studies showing that both controlled disease and IGF1 are associated with improved QoL (10,11,12).…”

Section: Introductioncontrasting

confidence: 54%

See 1 more Smart Citation

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Postma

Netea‐Maier²,

Berg³

et al. 2012

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: To assess the influence of long-acting somatostatin analogs (SSTA) after initial pituitary surgery on long-term health-related quality of life (HR-QoL) in relation to disease control in patients with acromegaly. Design: This is a cross-sectional study in two tertiary referral centers in The Netherlands. Patients and methods: One hundred and eight patients with acromegaly, in whom transsphenoidal (nZ101, 94%) or transcranial (nZ7, 6%) surgery was performed. Subsequently, 46 (43%) received additional radiotherapy and 41 (38%) were on postoperative treatment with SSTA because of persistent or recurrent disease at the time of study. All subjects filled in standardized questionnaires measuring HR-QoL. Disease control at the time of study was assessed by local IGF1 SDS. Results: IGF1 SDS were slightly higher in patients treated with SSTA in comparison with patients without use of SSTA (0.85G1.52 vs 0.25G1.21, PZ0.026), but the percentage of patients with insufficient control (IGF1 SDS O2) was not different (17 vs 9%, PZ0.208). Patients using SSTA reported poorer scores on most subscales of the RAND-36 and the acromegaly QoL and on all subscales of the multidimensional fatigue inventory-20. A subgroup analysis in patients with similar IGF1 levels (SSTAC, nZ26, IGF1 SDS 0.44G0.72 vs SSTAK, nZ44, IGF1 SDS 0.41G0.65) revealed worse scores on physical functioning, physical fatigue, reduced activity, vitality, and general health perception across all HR-QoL questionnaires in patients treated with SSTA. Conclusion: QoL is impaired in association with the need for prolonged postoperative therapy by SSTA in patients with acromegaly despite similar IGF1 levels.

show abstract

Quality of Life in Acromegaly and Growth Hormone Deficiency

Webb

Resmini

Santos

et al. 2011

Growth Hormone Related Diseases and Therapy

View full text Add to dashboard Cite

Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL)

Cited by 82 publications

References 39 publications

Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian Registry on acromegaly

Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian Registry on acromegaly

Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly

Quality of Life in Acromegaly and Growth Hormone Deficiency

Contact Info

Product

Resources

About